The relationship between high-dose corticosteroid treatment and mortality in acute respiratory distress syndrome: a retrospective and observational study using a nationwide administrative database in Japan

Table 1 Baseline characteristics of the patients treated with or without high-dose corticosteroid before and after group adjustment

	Before adjustment			After adjustment
	High-dose corticosteroid (n = 927)	Non-high-dose corticosteroid (n = 1780)	p-value	High-dose corticosteroid (n = 927)	Non-high-dose corticosteroid (n = 1780)	p-value
Sex	68.1	66.9	0.562	68.1	67.8	0.771
Age (years)	71.6 ± 0.5	67.9 ± 0.5	< 0.001	67.7 ± 1.0	69.3 ± 0.4	0.05
Hospital volume per year	10.3 ± 0.3	13.0 ± 0.3	< 0.001	12.2 ± 0.6	12.1 ± 0.2	0.806
Sepsis	12.1	22.1	< 0.001	19.9	19	0.373
Cancer	12.3	8.3	0.001	10.2	9.7	0.487
Pneumonia	52.6	62.4	< 0.001	63.6	60.3	< 0.001
Pancreatitis	0.3	1.1	0.041	0.4	0.8	0.001
Lung and abdominal trauma	0.1	0.7	0.043	0.2	0.4	0.009
Liver dysfunction	2.1	2.2	0.88	3.0	2.2	0.392
Hemodialysis	10.1	13.1	0.023	14.0	12.4	0.085
Neurological dysfunction	10.6	22.5	< 0.001	21.8	18.8	0.034
Shock	44.2	48.1	0.053	47.4	47.2	0.848
Insulin	61.7	45.9	< 0.001	48.7	51.2	0.016
Antithrombin III	9.0	15.4	< 0.001	13.9	13.2	0.537
rhTM	10.0	14.1	0.002	14.6	12.9	0.159
Heparin	58.2	61.5	0.094	62.8	61.7	0.088
Protease inhibitors	17.8	19.4	0.318	20.1	19.2	0.331
Sivelestat	72.9	56.2	< 0.001	59.7	61.8	0.074
Platelet transfusion	8.0	10.2	0.045	9.7	9.7	0.938
Red blood cell transfusion	16.4	26.5	< 0.001	24.8	23.3	0.241
Albumin administration	31.7	41.6	< 0.001	38.9	38.5	0.706
Immunoglobulin administration	18.1	23.5	0.001	22.2	21.8	0.637
Intensive-care unit	33.3	32.9	0.852	33.7	33.4	0.754

Data are presented as the % or mean ± standard error, unless otherwise stated. Groups were adjusted using the inverse probability of treatment weighting method
rhTM recombinant human soluble thrombomodulin

ISSN: 1471-2466